Journal article
Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up
J Trotman, S Opat, D Gottlieb, D Simpson, P Marlton, G Cull, J Munoz, A Tedeschi, AW Roberts, JF Seymour, SK Atwal, Y Yu, W Novotny, E Holmgren, Z Tan, JD Hilger, J Huang, CS Tam
Blood | AMER SOC HEMATOLOGY | Published : 2020
Abstract
Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients withWM who were either treatmentna ïve (TN) or had relapsed/refractory (R/R) disease. Patients had disease requiring treatment per InternationalWorkshop onWaldenströmMacroglobulinemia (IWWM) criteria. Treatment was 160 mg of oral zanubrutinib twice daily (n 5 50) or 320 mg once daily (n 5 23). Efficacy endpoints included overall response rate (ORR) and very good partial response/complete response (VGPR/CR) rates per IWWM-6 criteria (with modification of VGPR de..
View full abstractGrants
Funding Acknowledgements
The authors thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centers. This study was supported by research funding from BeiGene (Beijing) Co., Ltd. (Beijing, China). Medical writing and editorial assistance were funded by BeiGene and provided by Gordon Bray and Bio Connections (Chicago, IL).